ライフサイエンスコーパス: heparin-induced thrombocytopenia

1 th an immune-mediated adverse drug reaction, heparin-induced thrombocytopenia.

2 ntibodies can induce the adverse drug effect heparin-induced thrombocytopenia.

3 a synthetic heparin with a reduced effect of heparin-induced thrombocytopenia.

4 thrombocytopenia in the clinical syndrome of heparin-induced thrombocytopenia.

5 bilateral adrenal hemorrhage associated with heparin-induced thrombocytopenia.

6 ed with a variety of diagnoses and suspected heparin-induced thrombocytopenia.

7 myocardium, near infrared spectroscopy, and heparin-induced thrombocytopenia.

8 agulation monitoring and a reduced incidence heparin-induced thrombocytopenia.

9 ivity has been targeted for the treatment of heparin-induced thrombocytopenia.

10 tics without the dangerous adverse effect of heparin-induced thrombocytopenia.

11 t resembles the pathogenesis of (autoimmune) heparin-induced thrombocytopenia.

12 w to approach clinical complications such as heparin-induced thrombocytopenia.

13 inst PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia.

14 ctive Abs are central to the pathogenesis of heparin-induced thrombocytopenia.

15 ial in the workup of patients with suspected heparin-induced thrombocytopenia.

16 ts with warfarin-associated VLG complicating heparin-induced thrombocytopenia.

17 atients with cancer-associated thrombosis or heparin-induced thrombocytopenia.

18 ivalirudin group had a greater occurrence of heparin-induced thrombocytopenia (12% vs 1%; p < 0.01) a

19 mpleted prospective clinical trial (HIT [for heparin-induced thrombocytopenia] 5801 study; n = 500) o

20 Patients were 960 patients with heparin-induced thrombocytopenia (767 argatroban-treated

21 The differential diagnosis (including heparin-induced thrombocytopenia), a plan for management

22 to platelet factor 4 (PF4), which underlies heparin-induced thrombocytopenia, a known side effect of

23 latelet factor 4 (PF4) to polyanions induces heparin-induced thrombocytopenia, a prothrombotic advers

24 io, 0.72 [0.38-1.36]), rates of bleeding and heparin-induced thrombocytopenia (adjusted odds ratio, 0

25 s can be clinical jargon (writing "HIT" for "heparin induced thrombocytopenia"), ambiguous terms that

26 but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill me

27 In the case of suspected or confirmed heparin-induced thrombocytopenia, an alternative anticoa

28 associated with platelet activation, such as heparin-induced thrombocytopenia and autoimmune thromboc

29 inical disease, such as platelet factor 4 in heparin-induced thrombocytopenia and beta(2)-glycoprotei

30 The frequencies of heparin-induced thrombocytopenia and catheter-related bl

31 iven by lower rates of pulmonary embolus and heparin-induced thrombocytopenia and corresponding lower

32 Prevalence of heparin-induced thrombocytopenia and heparin-induced thr

33 corporeal membrane oxygenator (prevalence of heparin-induced thrombocytopenia and heparin-induced thr

34 baseline thrombocytopenia was uncommon, and heparin-induced thrombocytopenia and platelet factor 4/h

35 phase 1 clinical trial for the treatment of heparin-induced thrombocytopenia and received a fast-tra

36 , particularly ischemic stroke, is common in heparin-induced thrombocytopenia and significantly incre

37 itself to venous thrombus in the setting of heparin-induced thrombocytopenia and subsequent arterial

38 ssue of Blood, Rollin et al demonstrate that heparin-induced thrombocytopenia and thrombosis (HIT) pa

39 (PF4)/heparin complexes are the hallmark of heparin-induced thrombocytopenia and thrombosis (HIT), b

40 Heparin-induced thrombocytopenia and thrombosis (HITT) i

41 al and cardiac ICU who were presumed to have heparin-induced thrombocytopenia and underwent antiplate

42 All cases confirmed known characteristics of heparin-induced thrombocytopenia and uniformly revealed

43 ee patients (23.1%) had laboratory-confirmed heparin-induced thrombocytopenia, and all of them develo

44 or flush through the lumen (flush failure), heparin-induced thrombocytopenia, and catheter-related b

45 licated by another saddle pulmonary embolus, heparin-induced thrombocytopenia, and COVID-19 infection

46 patients at 14 and 45 days, major bleeding, heparin-induced thrombocytopenia, and length of stay.

47 gnosis of storage pool disease, diagnosis of heparin-induced thrombocytopenia, and measurement of the

48 he biology of PF4-heparin complex formation, heparin-induced thrombocytopenia antibody binding occurs

49 olded PF4-M2 state, strongly suggesting that heparin-induced thrombocytopenia antibody recognizes a l

50 An immunoglobulin G class "heparin-induced thrombocytopenia antibody" attaches to a

51 age autoimmune thrombotic disorders, such as heparin-induced thrombocytopenia, antiphospholipid syndr

52 Acquired hypercoagulable disorders such as heparin-induced thrombocytopenia, antiphospholipid syndr

53 ombocytopenia (platelet count <150 x103/uL), heparin-induced thrombocytopenia (as diagnosed by the tr

54 bstructive pulmonary disease (COPD), type II heparin-induced thrombocytopenia, atrial fibrillation, p

55 e evaluation and management of patients with heparin-induced thrombocytopenia, but also the measures

56 Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor pati

57 rhage and insufficiency as a complication of heparin-induced thrombocytopenia, coupled with the catas

58 electrode aggregometry was assessed against heparin-induced thrombocytopenia diagnosis (clinical pic

59 ight patients met the algorithm criteria for heparin-induced thrombocytopenia diagnosis and seven of

60 Using heparin-induced thrombocytopenia diagnosis as reference,

61 pid and easy to perform functional assay for heparin-induced thrombocytopenia diagnosis in ICU patien

62 lectrode aggregometry performed very well in heparin-induced thrombocytopenia diagnosis in ICU patien

63 Heparin-induced thrombocytopenia diagnosis was retained

64 ays significantly improve the specificity of heparin-induced thrombocytopenia diagnosis, but they are

65 s and agreed with the gold standard test for heparin-induced thrombocytopenia diagnosis, the serotoni

66 embrane oxygenator; had significantly higher heparin-induced thrombocytopenia enzyme-linked immunosor

67 hough still considered experimental, TPE for heparin-induced thrombocytopenia for urgent cardiac surg

68 Heparin-induced thrombocytopenia had no effect on mortal

69 Bilateral adrenal hemorrhage associated with heparin-induced thrombocytopenia has become an increasin

70 nd antibodies from patients with spontaneous heparin-induced thrombocytopenia (HIT) and classical HIT

71 n thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT) and immune thromb

72 ents in understanding the pathophysiology of heparin-induced thrombocytopenia (HIT) and in applying t

73 athophysiology of VITT is similar to that of heparin-induced thrombocytopenia (HIT) and is associated

74 mediated platelet activation is essential in heparin-induced thrombocytopenia (HIT) and other immune-

75 rin antibodies and anti-PF4 antibodies cause heparin-induced thrombocytopenia (HIT) and vaccine-induc

76 Heparin-induced thrombocytopenia (HIT) antibodies recogn

77 Early recognition and treatment of heparin-induced thrombocytopenia (HIT) are crucial to pr

78 al describe a novel diagnostic algorithm for heparin-induced thrombocytopenia (HIT) based on the 4Ts

79 rin reexposure despite a history of previous heparin-induced thrombocytopenia (HIT) can be appropriat

80 planation why only a subset of patients with heparin-induced thrombocytopenia (HIT) develop clinicall

81 Current methods of treating heparin-induced thrombocytopenia (HIT) focus on treatmen

82 Thrombosis results in heparin-induced thrombocytopenia (HIT) from cellular act

83 A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed

84 Laboratory testing for heparin-induced thrombocytopenia (HIT) has important sho

85 exchange (TPE) has been advocated to remove heparin-induced thrombocytopenia (HIT) IgG antibodies be

86 Heparin-induced thrombocytopenia (HIT) is a life- and li

87 Heparin-induced thrombocytopenia (HIT) is a life-threate

88 Heparin-induced thrombocytopenia (HIT) is a life-threate

89 Heparin-induced thrombocytopenia (HIT) is a life-threate

90 Heparin-induced thrombocytopenia (HIT) is a major cause

91 Heparin-induced thrombocytopenia (HIT) is a potentially

92 Heparin-induced thrombocytopenia (HIT) is a potentially

93 Heparin-induced thrombocytopenia (HIT) is a prothromboti

94 Heparin-induced thrombocytopenia (HIT) is a prothromboti

95 Heparin-induced thrombocytopenia (HIT) is a prothromboti

96 Heparin-induced thrombocytopenia (HIT) is a prothromboti

97 Heparin-induced thrombocytopenia (HIT) is a relatively c

98 Heparin-induced thrombocytopenia (HIT) is a significant

99 Heparin-induced thrombocytopenia (HIT) is a thrombotic c

100 Heparin-induced thrombocytopenia (HIT) is an adverse dru

101 Heparin-induced thrombocytopenia (HIT) is an antibody-me

102 Heparin-induced thrombocytopenia (HIT) is an autoimmune

103 Heparin-induced thrombocytopenia (HIT) is an immune comp

104 Heparin-induced thrombocytopenia (HIT) is an immune-medi

105 Heparin-induced thrombocytopenia (HIT) is an immune-medi

106 Heparin-induced thrombocytopenia (HIT) is an immune-medi

107 Heparin-induced thrombocytopenia (HIT) is an immune-medi

108 Heparin-induced thrombocytopenia (HIT) is an important,

109 Heparin-induced thrombocytopenia (HIT) is caused by anti

110 Heparin-induced thrombocytopenia (HIT) is caused by plat

111 Heparin-induced thrombocytopenia (HIT) is characterized

112 Prompt diagnostic evaluation of suspected heparin-induced thrombocytopenia (HIT) is critical for g

113 Heparin-induced thrombocytopenia (HIT) is due primarily

114 Heparin-induced thrombocytopenia (HIT) is due to immunog

115 Rapid laboratory assessment of heparin-induced thrombocytopenia (HIT) is important for

116 Heparin-induced thrombocytopenia (HIT) is initiated by a

117 Rapid exclusion of heparin-induced thrombocytopenia (HIT) is needed to dete

118 ies of thrombocytopenia in critical illness, heparin-induced thrombocytopenia (HIT) is one potential

119 Heparin-induced thrombocytopenia (HIT) is suspected much

120 cal mechanism similar to that of spontaneous heparin-induced thrombocytopenia (HIT) is suspected, wit

121 Life-threatening heparin-induced thrombocytopenia (HIT) is treated with t

122 Current guidelines for heparin-induced thrombocytopenia (HIT) management recomm

123 Monoclonal Abs against PF4 and IgG from a heparin-induced thrombocytopenia (HIT) patient were appl

124 Patients with heparin-induced thrombocytopenia (HIT) remain at risk fo

125 The diagnosis of heparin-induced thrombocytopenia (HIT) requires detectio

126 The existence of spontaneous heparin-induced thrombocytopenia (HIT) syndrome (or auto

127 ermine spectral markers for the diagnosis of heparin-induced thrombocytopenia (HIT), a difficult-to-d

128 aggregates implicated in the development of heparin-induced thrombocytopenia (HIT), a potentially fa

129 thrombotic thrombocytopenic purpura (TTP) or heparin-induced thrombocytopenia (HIT), and Trousseau sy

130 odies to platelet factor 4 (PF4) involved in heparin-induced thrombocytopenia (HIT), beta-2-glycoprot

131 nheparin anticoagulants for the treatment of heparin-induced thrombocytopenia (HIT), few data are ava

132 syndrome (TTS), a rare condition resembling heparin-induced thrombocytopenia (HIT), have been observ

133 VITT appears to be similar to heparin-induced thrombocytopenia (HIT), with both disord

134 abel treatments(rivaroxaban, dabigatran) for heparin-induced thrombocytopenia (HIT),and also outline

135 ggesting that NA-PF4 can potentially cause a heparin-induced thrombocytopenia (HIT)-like prothromboti

136 most frequent drug-induced immune disorder, heparin-induced thrombocytopenia (HIT).

137 4Ts is a pretest clinical scoring system for heparin-induced thrombocytopenia (HIT).

138 g to the prothrombotic adverse drug reaction heparin-induced thrombocytopenia (HIT).

139 ACs) are attractive options for treatment of heparin-induced thrombocytopenia (HIT).

140 the diagnostic accuracy of immunoassays for heparin-induced thrombocytopenia (HIT).

141 the antibody-mediated adverse drug effect of heparin-induced thrombocytopenia (HIT).

142 ntibodies are central to the pathogenesis of heparin-induced thrombocytopenia (HIT).

143 icoagulant that can cause a condition called heparin-induced thrombocytopenia (HIT).

144 ory assessment for thrombosis, bleeding, and heparin-induced thrombocytopenia [HIT]).

145 ion that occurs in a subset of patients with heparin-induced thrombocytopenia (HITT).

146 cytic leukemia; (4) do not test or treat for heparin-induced thrombocytopenia if the clinical pretest

147 in reactions in 1.80% (95% CI, 1.34%-2.37%), heparin-induced thrombocytopenia in 0%, thrombocytopenia

148 The frequency of heparin-induced thrombocytopenia in extracorporeal membr

149 al density threshold less than 1 to rule out heparin-induced thrombocytopenia in patients on extracor

150 ith (6/19, 31.6%) or without (89/279, 32.2%) heparin-induced thrombocytopenia in patients on extracor

151 There was no difference in prevalence of heparin-induced thrombocytopenia in patients on venoveno

152 the Pretest Probability Score in identifying heparin-induced thrombocytopenia in patients post cardio

153 munosorbent assay should be used to identify heparin-induced thrombocytopenia in patients with multip

154 reveal a high occurrence of overdiagnosis of heparin-induced thrombocytopenia in surgical patients wi

155 Overtreatment of heparin-induced thrombocytopenia in the surgical ICU con

156 Heparin-induced thrombocytopenia is a common adverse eff

157 Heparin-induced thrombocytopenia is a profoundly dangero

158 Heparin-induced thrombocytopenia is a prothrombotic adve

159 Heparin-induced thrombocytopenia is a prothrombotic diso

160 Heparin-induced thrombocytopenia is a recognized concern

161 Heparin-induced thrombocytopenia is a relatively common

162 Delayed-onset heparin-induced thrombocytopenia is increasingly being r

163 The immune response in heparin-induced thrombocytopenia is initiated by and dir

164 penia if the clinical pretest probability of heparin-induced thrombocytopenia is low; and (5) do not

165 Heparin-induced thrombocytopenia is more frequent in bot

166 t count trends to guide decision to test for heparin-induced thrombocytopenia is not an optimal strat

167 platelet factor 4 antibodies reminiscent of heparin-induced thrombocytopenia, leading to a prothromb

168 hemorrhage, the state of thrombocytopenia in heparin-induced thrombocytopenia leads to an acquired hy

169 unosorbent assay optical density thresholds, heparin-induced thrombocytopenia negative was defined as

170 tive patients (100%) compared with 19 of 125 heparin-induced thrombocytopenia-negative patients (15%)

171 Stroke in heparin-induced thrombocytopenia occurs most often in fe

172 ften life threatening in patients undergoing heparin-induced thrombocytopenia or sepsis.

173 ation may be a result of atheroembolization, heparin-induced thrombocytopenia, or hypoperfusion.

174 latelet functional assay that could decrease heparin-induced thrombocytopenia overdiagnosis in the IC

175 There was no difference in mortality between heparin-induced thrombocytopenia positive and negative p

176 ined as an optical density less than 1.0 and heparin-induced thrombocytopenia positive as an optical

177 Heparin-induced thrombocytopenia positive patients were

178 orbent assay; 10 patients were identified as heparin-induced thrombocytopenia positive.

179 troban, lepirudin, or fondaparinux: 10 of 10 heparin-induced thrombocytopenia-positive patients (100%

180 Heparin-induced thrombocytopenia-positive patients were

181 severe thrombocytopenia, and within 2 wks of heparin-induced thrombocytopenia presentation.

182 Heparin-induced thrombocytopenia presents 5 to 12 days a

183 mune thrombotic thrombocytopenia (VITT), and heparin-induced thrombocytopenia prompted recognition of

184 ence of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia related thrombosis, 8.3

185 ence of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia-related thrombosis amon

186 The optimal criteria for diagnosis of heparin-induced thrombocytopenia remain unclear, contrib

187 Overdiagnosis of heparin-induced thrombocytopenia remains an unresolved i

188 Heparin-induced thrombocytopenia represents a unique cli

189 Heparin-induced thrombocytopenia requires alternative an

190 omplexes (ICs) mediate inflammation, such as heparin-induced thrombocytopenia, rheumatoid arthritis,

191 comprehensive review, the authors highlight heparin-induced thrombocytopenia's risk factors, clinica

192 Moreover, CXCR7 agonist regulated heparin-induced thrombocytopenia-sera/immunoglobulin G-t

193 Heparin-induced thrombocytopenia testing results and pla

194 Pretest Probability Score and heparin-induced thrombocytopenia testing results were co

195 tional algorithm to interpret the results of heparin-induced thrombocytopenia testing.

196 rare vaccine-related variant of spontaneous heparin-induced thrombocytopenia that we refer to as vac

197 Antibodies associated with heparin-induced thrombocytopenia/ thrombosis (HITT) are

198 be demonstrated in almost all patients with heparin-induced thrombocytopenia/thrombosis (HIT/HITT) a

199 Heparin-induced thrombocytopenia/thrombosis (HIT/HITT) i

200 Heparin-induced thrombocytopenia/thrombosis (HIT/T) is a

201 Heparin-induced thrombocytopenia/thrombosis (HIT/T) is t

202 peutic effect and can also cause thrombosis (heparin-induced thrombocytopenia/thrombosis syndrome).

203 ications for TPE for cardiac surgery include heparin-induced thrombocytopenia, thrombotic thrombocyto

204 itted to surgical ICUs and were suspected of heparin-induced thrombocytopenia to identify how often p

205 etrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II; NCT01304238).

206 lateral adrenal hemorrhage in the setting of heparin-induced thrombocytopenia uniformly presenting wi

207 a, WI) enzyme-linked immunosorbent assay for heparin-induced thrombocytopenia using the carbon-14 ser

208 of Pretest Probability Score in identifying heparin-induced thrombocytopenia was lower in extracorpo

209 isastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hos

210 eir niche for the treatment of patients with heparin-induced thrombocytopenia, whereas bivalirudin is

211 Heparin-induced thrombocytopenia with platelet factor 4/

212 Heparin-induced thrombocytopenia with thrombosis (HITT)

213 ew stroke and stroke-associated mortality in heparin-induced thrombocytopenia without increasing intr

214 may aid clinicians in objectively ruling out heparin-induced thrombocytopenia without sending a confi

215 roves clinical outcomes in patients who have heparin-induced thrombocytopenia, without increasing ble